methods communications
Optimized bacterial expression of a synthetic BRIL antibody
aSir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom
*Correspondence e-mail: [email protected], [email protected]
The use of monoclonal fragments antigen binding (Fabs) is a prevalent methodology facilitating protein structure determination via both crystallography and cryo-EM. The development of a synthetic Fab against the BRIL domain improved the accessibility of this approach, providing a general fiducial applicable to any protein of interest via the simple curation of a BRIL fusion protein. Here, we document the generation of a T7 Express ΔcybC strain allowing contaminant-free bacterial expression of the synthetic anti-BRIL Fab BAG2. We also report the crystal structure of BAG2 in complex with native cytochrome b562, a complex arising from expression in canonical Escherichia coli strains.
Keywords: cryo-EM; X-ray crystallography; BRIL; synthetic antibodies; fiducials.
1. Introduction
Single-particle analysis cryo-electron microscopy (SPA cryoEM) has become the primary workhorse for high-resolution protein structure elucidation in recent years owing to its low sample requirements and its wider accommodation of heterogeneous samples and/or complexes (De Zorzi et al., 2016
; Chua et al., 2022
). Nevertheless, macromolecule size remains a fundamental limitation within SPA cryoEM, with substantially fewer high-resolution reconstructions performed for macromolecules below 100 kDa; thus, certain protein classes remain underrepresented.
SPA cryoEM presents an attractive proposition for the structural study of integral membrane proteins, which typically exhibit more incompatibilities with X-ray crystallography or NMR. Nonetheless, integral membrane proteins are typically smaller than 100 kDa; thus, several techniques to append membrane proteins, increasing their applicability for cryoEM, have been developed.
Monoclonal fragments antigen binding (Fabs) present one such methodology to assist the structural elucidation of small membrane proteins. Initially Fabs were utilized to assist membrane-protein crystallization, whereby their large polar surface area facilitates crystal contact formation (Kermani, 2021
). Subsequently Fabs were deployed as fiducials in cryoEM, artificially increasing the particle mass by ∼50 kDa and facilitating image alignment, enabling the high-resolution elucidation of several membrane proteins below the 100 kDa threshold (Wu et al., 2012
; Walsh et al., 2018
; Kim et al., 2019
; Shionoya et al., 2024
; Pan et al., 2020
).
The generation of Fabs against each protein of interest presents a substantial bottleneck in their application to nascent projects. Nevertheless, a recently developed panel of synthetic Fabs raised against the BRIL domain offer universal fiducials which may be applied to any target via assembly of a protein–BRIL fusion (Mukherjee et al., 2020
; Tsutsumi et al., 2020
; Sverak et al., 2024
; Luo et al., 2025
; Zhang et al., 2025
).
We sought to apply this methodology to a small membrane protein of interest within our laboratory; however, we observed the anti-BRIL Fab (BAG2) to co-purify with the soluble cytochrome b562 when grown in typical Escherichia coli expression strains. Here, we report the generation of a T7 Express ΔcybC strain, offering an alternative bacterial system for the expression of BAG2 which completely prevents the co-purification of cytochrome b562.
2. Materials and methods
2.1. Overexpression and purification of BAG2
E. coli expression strains [BL21-Gold, Rosetta (DE3), C43 (DE3) Pro+, T7 Express and T7 Express ΔcybC] were transformed with a pRH2.2 expression vector harbouring the synthetic, anti-BRIL Fab BAG2 (Mukherjee et al., 2020
). Cultures were grown at 37°C in 2×YT medium supplemented with 100 µg ml−1 carbenicillin and 1 mM MgSO4 until the OD600 reached 0.6. Protein expression was induced by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and continued for 4 h at 37°C.
Cells were harvested via centrifugation at 6000g for 15 min. The cell pellets were resuspended in an appropriate volume of 50 mM Tris, 500 mM NaCl pH 8 supplemented with cOmplete EDTA-free protease-inhibitor cocktail tablets (Roche). The cells were lysed via four passes through an Emulsiflex-C3 cell disruptor (Avestin). The cell lysate was incubated at 58°C for 30 min to denature bacterial proteins before cell debris was removed via centrifugation at 50 000g for 1 h at 4°C. The resulting supernatant was filtered through a 0.22 µm syringe filter and bound to a HiTrap Protein L column (Cytiva) pre-equilibrated in 50 mM Tris, 500 mM NaCl pH 8. The column was washed with 10 column volumes (CV) of 50 mM Tris, 500 mM NaCl pH 8 and the protein was eluted with 0.1 M acetic acid. Fractions containing BAG2 were pooled and loaded onto a 1 ml RESOURCE S column (Cytiva) pre-equilibrated in 50 mM sodium acetate pH 5.0. The column was washed with 5 CV of 50 mM sodium acetate pH 5.0 and the protein was eluted using a linear gradient to 100% 50 mM sodium acetate, 2 M NaCl pH 5.0 over 25 CV. Fractions containing BAG2 were dialysed overnight at 4°C against 20 mM Tris, 150 mM NaCl pH 8, concentrated in a 10 kDa molecular-weight cutoff (MWCO) concentrator (Sartorius) and snap-frozen for later use.
2.2. BAG2–BRIL fusion-protein complex formation
BAG2 was combined with BRIL fusion protein at a 1.2× molar excess, incubated on ice for 60 min and injected onto a Superose 6 10/300 Increase column (Cytiva). Successful complex formation was established via the analysis of elution fractions by SDS–PAGE.
2.3. Crystallization and structure determination of the cytochrome b562–BAG2 complex
Fractions corresponding to the cytochrome b562–BAG2 complex were pooled and concentrated to 5–10 mg ml−1 in a 50 kDa MWCO concentrator (Sartorius). Crystallization screens were prepared by mixing 100 nl cytochrome b562–BAG2 complex and 100 nl precipitant solution. The complex crystallized in space group P65 (a = 88.72, b = 88.72, c = 162.51 Å, α = 90, β = 90, γ = 120°) in a precipitant solution from the Morpheus screen (Gorrec, 2009
) comprising 0.1 M MOPS/HEPES–Na pH 7.5, 0.03 M bromide, 0.03 M fluoride, 0.03 M imidazole, 12.5%(w/v) PEG 1000, 12.5%(w/v) PEG 3350, 12.5%(v/v) MPD. Diffraction data were collected on beamline I04 at Diamond Light Source (DLS). Data reduction and processing was performed using the xia2–DIALS pipeline (Winter et al., 2018
; Winter, 2010
).
The crystal structure of the native cytochrome b562–BAG2 complex was solved by molecular replacement with a modified version of the BAG2–BRIL domain structure (PDB entry 6cbv) in which the BRIL domain was replaced with cytochrome b562, using Phaser (McCoy et al., 2007
). The resulting model was refined using Phenix (Liebschner et al., 2019
) interspersed with manual inspection and adjustment in Coot (Emsley & Cowtan, 2004
). Crystallization, diffraction data-collection and processing and refinement statistics are given in Tables 1
, 2
and 3
, respectively.
|
||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
2.4. Knockout generation
The T7 Express ΔcybC strain was derived from T7 Express (NEB) using lambda Red recombination, as described previously (Datsenko & Wanner, 2000
). Briefly, the aph cassette was amplified from donor plasmid pKD4 using primers oBFC307 and oBFC308 (Table 4
) and the linear product introduced to the parental T7 Express strain carrying the Red helper plasmid pKD46. Transformants were initially selected by growth on LB agar supplemented with 50 µg ml−1 kanamycin and the ΔcybC::aph allele verified by colony PCR using flanking primers oBFC309 and oBFC310 (Table 4
). Finally, the ΔcybC::aph allele was P1 transduced into a fresh T7 Express background as described previously (Thomason et al., 2007
).
|
||||||||||||||
3. Results
3.1. BAG2 co-purifies with cytochrome b562
Initially, BAG2 expression was performed according to Mukherjee et al. (2015
, 2020
) utilizing the E. coli BL21-Gold strain. Subsequent Protein-L and cation-exchange steps yielded a homogenous sample comprising the ∼25 kDa heavy (HC) and light chains (LC) of BAG2 and an unexpected species of ∼15 kDa, as indicated by SDS–PAGE (Figs. 1
a and 1
c). Expression of BAG2 in alternative E. coli expression strains [Rosetta (DE3), C43 (DE3) Pro+ and T7 Express] yielded identical results.
|
Figure 1
BAG2 co-purifies with a 15 kDa protein which competes for BRIL binding. (a) SDS–PAGE of Protein L elution fractions following BAG2 overexpression in BL21-Gold indicating co-purification of a 15 kDa protein, later confirmed as cytochrome b562. (b) Cation-exchange trace of pooled Protein L elution fractions following BAG2 overexpression in BL21-Gold. (c) SDS–PAGE of cation-exchange fractions following BAG2 overexpression in BL21-Gold, indicating that BAG2 maintains a stable complex with the 15 kDa protein later identified as cytochrome b562 throughout purification. (d) Region of interest from a size-exclusion chromatography trace following incubation of a BRIL fusion protein (∼37 kDa) with BAG2 purified from BL21-Gold indicating two distinct complexes with different retention volumes. The full trace, highlighting the region of interest, is provided as an inset at the top right. (e) SDS–PAGE of size-exclusion chromatography fractions following incubation of a BRIL fusion protein (∼37 kDa) with BAG2 purified from BL21-Gold. Fractions corresponding to complex 1 comprise the expected BRIL fusion protein–BAG2 complex, whilst complex 2 fractions comprise BAG2 in complex with the 15 kDa protein later identified as cytochrome b562. |
Originally, we presumed this ∼15 kDa species to arise from proteolytic degradation of BAG2; however, this seemed unlikely given that both species eluted from cation exchange within the same sharp peak (Fig. 1
b). Therefore, we proposed the ∼15 kDa band to indicate a co-purifying protein with high affinity for BAG2. This notion was supported via size-exclusion chromatography, which yielded two distinct species following incubation of our purified BAG2 sample with a BRIL fusion protein of ∼37 kDa (Fig. 1
d). SDS–PAGE indicated the larger species to comprise the expected BRIL fusion protein–BAG2 complex; however, the ∼15 kDa protein retained in a complex with a substantial proportion of BAG2, eluting as a second, smaller complex (Figs. 1
d and 1
e).
Both our purified BAG2 sample and SEC fractions comprising the ∼15 kDa protein exhibited a distinct red colour suggestive of an iron-containing molecule, whilst those corresponding to the desired BRIL fusion protein–BAG2 complex were clear. We therefore concluded that BAG2 was likely co-purifying with the native cytochrome b562 (hereafter referred to as cyt b562) present within the E. coli periplasm (Itagaki & Hager, 1966
). Indeed, BRIL is itself a thermostabilized derivative of apocytochrome b562 (Chun et al., 2012
); thus, the ability of the native cytochrome to compete with BRIL for BAG2 binding is unsurprising.
3.2. Determination of the cytochrome b562–BAG2 complex
To confirm our hypothesis that BAG2 was co-purifying with the native cyt b562, we sought to solve the structure of their complex. The cyt b562–BAG2 complex crystallized in space group P65 and diffracted to 2.65 Å resolution, with one copy of each protein in the asymmetric unit (Fig. 2
a), resulting in a Matthews coefficient of 3.15 Å3 Da−1 (Matthews, 1968
) and a corresponding solvent content of 61%.
|
Figure 2
Crystal structure of BAG2 in complex with cytochrome b562. (a) Crystal structure of the cytochrome b562–BAG2 complex in cartoon representation. (b) Alignment of our cyt b562–BAG2 structure (blue) with the previously determined BRIL–BAG2 structure (pink; PDB entry 6cbv). (c) Interaction of BAG2 (heavy and light chains in orange and blue, respectively) with cytochrome b562 (depicted as a purple surface). Brackets denote the contributing region of BAG2. (d) Overlaid CDR binding modes of BAG2 in complex with cytochrome b562 and BRIL. Heavy and light chains are coloured orange and blue, respectively, for the cytochrome b562-bound structure and gold and purple, respectively, for the BRIL-bound structure (PDB entry 6cbv). (e) Refined electron density for the BAG2 CDR regions interacting with cytochrome b562. The 2mFo − DFc map (grey mesh) is contoured at 1σ and BAG2 is displayed in ball-and-stick representation, coloured by B factor. (f) Refined electron density for the cytochrome b562 heme group. The 2mFo − DFc map (grey mesh) is contoured at 1σ and the heme group is displayed in ball-and-stick representation. |
As expected, our cyt b562–BAG2 complex exhibited an almost identical architecture to that of the previously educated BRIL–BAG2 complex (PDB entry 6cbv), with alignment yielding an r.m.s.d. of 0.539 Å across 529 pruned atom pairs and 0.686 Å across all 539 pairs (Fig. 2
b). Furthermore, the BAG2 complementarity-determining regions (CDRs) exhibit the same binding mode in both structures, in which both CDR-H2 and CDR-H3 supplement extensive interactions made by the LC CDRs (Figs. 2
c and 2
d). The average B factors for our cyt b562–BAG2 complex are relatively high (109 Å2), likely arising due to the high solvent content of the crystal; nevertheless, the electron density for the BAG2 CDRs was well defined, allowing accurate modelling of their interaction with cyt b562 (Fig. 2
e). Furthermore, unambiguous density was observed for the heme molecule within the cytochrome (Fig. 2
f). Our cyt b562–BAG2 crystal structure demonstrates the ability of BAG2 to form a stable complex with the native cytochrome b562 present within canonical E. coli expression strains.
3.3. Generation of a ΔcybC strain for bacterial BAG2 expression
Given the propensity of BAG2 to bind native cytochrome b562, we investigated possible methods to prevent their co-purification entirely. We noted the superfluous nature of cyt b562 given that disruption of the cybC gene prevents its expression in E. coli K strains (Trower, 1993
). Thus, we hypothesized that deletion of the cybC gene from a typical B-lineage E. coli expression strain would directly enable contaminant-free BAG2 expression and purification.
Utilizing Datsenko and Wanner gene inactivation, we replaced the cybC ORF within the E. coli T7 Express strain with a kanamycin cassette and subsequently P1-transduced the mutant allele into a fresh background (Figs. 3
a and 3
b). Expression utilizing this engineered strain, followed by the same Protein L and cation-exchange purification, yielded a pure BAG2 sample (Figs. 3
c, 3
d and 3
e) that formed only the desired BRIL fusion protein–BAG2 complex (Figs. 3
f and 3
g). Indeed, in our hands, BAG2 was sufficiently clean following Protein L purification that the elution fractions may be dialysed directly, avoiding the necessity for a subsequent cation-exchange step (Fig. 3
c).
|
Figure 3
Generation of a ΔcybC strain for bacterial BAG2 expression. (a) Gel electrophoresis of colony PCR amplifying the WT T7 Express cybC locus using flanking primers. (b) Gel electrophoresis of colony PCR amplifying the T7 Express ΔcybC::aph locus using flanking primers. (c) SDS–PAGE of Protein L elution fractions following BAG2 overexpression in T7 Express ΔcybC indicating no co-purifying proteins. (d) Cation-exchange trace of pooled Protein L elution fractions following BAG2 overexpression in T7 Express ΔcybC. (e) SDS–PAGE of cation-exchange fractions following BAG2 overexpression in T7 Express ΔcybC. (f) Size-exclusion chromatography trace following incubation of a BRIL fusion protein (∼37 kDa) with BAG2 purified from T7 Express ΔcybC indicating complete formation of the desired complex. (g) SDS–PAGE of the size-exclusion chromatography fractions following incubation of a BRIL fusion protein (∼37 kDa) with BAG2 purified from T7 Express ΔcybC. |
4. Discussion and conclusions
The use of monoclonal fragments antigen binding (Fabs) is a prevalent methodology facilitating protein structure determination via both crystallography and cryo-EM. The development of a synthetic Fab against the BRIL domain improved accessibility to this approach, providing a general fiducial applicable to any protein of interest via the simple curation of a BRIL fusion protein (Mukherjee et al., 2020
).
We observed BAG2 to co-purify with the native E. coli cytochrome b562, which hindered the assembly of our desired BRIL fusion protein–BAG2 complex (Figs. 1
d and 1
e). Consequently, we constructed a T7 Express ΔcybC strain, allowing the production of a pure BAG2 sample from a simple Protein L purification (Fig. 3
c).
Nonetheless, we emphasize that several publications have previously expressed and purified BAG2 from unmodified E. coli strains without issue (Mukherjee et al., 2020
; Sverak et al., 2024
; Tsutsumi et al., 2020
); thus, the maintained interaction between BAG2 and cyt b562 appears to result from minor differences during purification. Indeed, Mukherjee et al. (2020
) recommend incubation of the bacterial lysate at 60–63°C for 30 min to denature bacterial proteins and Fab degradation products. In contrast, our incubation at 58°C for the same duration appears to be insufficient to completely dissociate the unwanted complex, implying the incubation temperature to be a critical factor in ensuring efficacious purification of BAG2 from canonical E. coli expression strains.
Nevertheless, our T7 Express ΔcybC strain offers an alternative bacterial system for the expression of BAG2, which completely prevents its association with cytochrome b562 whilst also providing an efficient and affordable substitute to the insect and mammalian systems also utilized (Dang et al., 2022
; Kugawa et al., 2025
). Whilst we demonstrated the efficacy of our ΔcybC strain for BAG2, we speculate that it may also provide a useful resource for the expression of any previously developed synthetic anti-BRIL Fab (BAG5, BAK5 and BAK7; Mukherjee et al., 2020
).
Acknowledgements
We thank Anthony Kossiakoff and Somnath Mukherjee, University of Chicago, for the kind gift of the BAG2 expression construct and protocols. We also thank Ed Lowe and the beamline scientists at Diamond Light Source for their help with crystallographic data collection and access to beamline I04 under proposal mx38144.
Conflict of interest
The authors declare no conflicts of interest.
Data availability
The structure factors and model of the native cytochrome b562–BAG2 complex have been deposited in the Protein Data Bank (PDB entry 9tmp).
Funding information
We would like to thank the following funding sources: MR/W016672/1 (MRC Career Development Award to GLI) and 101162143 – LipidBarriers (ERC Starting Grant Awarded to GLI).
References
Chua, E. Y. D., Mendez, J. H., Rapp, M., Ilca, S. L., Tan, Y. Z., Maruthi, K., Kuang, H., Zimanyi, C. M., Cheng, A., Eng, E. T., Noble, A. J., Potter, C. S. & Carragher, B. (2022). Annu. Rev. Biochem. 91, 1–32.
Web of Science
CrossRef
CAS
PubMed
Google Scholar
Chun, E., Thompson, A. A., Liu, W., Roth, C. B., Griffith, M. T., Katritch, V., Kunken, J., Xu, F., Cherezov, V., Hanson, M. A. & Stevens, R. C. (2012). Structure, 20, 967–976.
Web of Science
CrossRef
CAS
PubMed
Google Scholar
Dang, Y., Zhou, D., Du, X., Zhao, H., Lee, C.-H., Yang, J., Wang, Y., Qin, C., Guo, Z. & Zhang, Z. (2022). Cell. Discov. 8, 141.
CrossRef
PubMed
Google Scholar
Datsenko, K. A. & Wanner, B. L. (2000). Proc. Natl Acad. Sci. USA, 97, 6640–6645.
Web of Science
CrossRef
PubMed
CAS
Google Scholar
De Zorzi, R., Mi, W., Liao, M. & Walz, T. (2016). Microscopy (Tokyo), 65, 81–96.
CrossRef
Google Scholar
Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132.
Web of Science
CrossRef
CAS
IUCr Journals
Google Scholar
Gorrec, F. (2009). J. Appl. Cryst. 42, 1035–1042.
Web of Science
CrossRef
CAS
IUCr Journals
Google Scholar
Itagaki, E. & Hager, L. P. (1966). J. Biol. Chem. 241, 3687–3695.
CrossRef
PubMed
Google Scholar
Kermani, A. A. (2021). FEBS J. 288, 5788–5804.
CrossRef
PubMed
Google Scholar
Kim, J., Tan, Y. Z., Wicht, K. J., Erramilli, S. K., Dhingra, S. K., Okombo, J., Vendome, J., Hagenah, L. M., Giacometti, S. I., Warren, A. L., Nosol, K., Roepe, P. D., Potter, C. S., Carragher, B., Kossiakoff, A. A., Quick, M., Fidock, D. A. & Mancia, F. (2019). Nature, 576, 315–320.
Web of Science
CrossRef
CAS
PubMed
Google Scholar
Kugawa, M., Kawakami, K., Kise, R., Suomivuori, C.-M., Tsujimura, M., Kobayashi, K., Kojima, A., Inoue, W. J., Fukuda, M., Matsui, T. E., Fukunaga, A., Koyanagi, J., Kim, S., Ikeda, H., Yamashita, K., Saito, K., Ishikita, H., Dror, R. O., Inoue, A. & Kato, H. E. (2025). Nat. Commun. 16, 2809.
CrossRef
PubMed
Google Scholar
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K., Prisant, M. G., Read, R. J., Richardson, J. S., Richardson, D. C., Sammito, M. D., Sobolev, O. V., Stockwell, D. H., Terwilliger, T. C., Urzhumtsev, A. G., Videau, L. L., Williams, C. J. & Adams, P. D. (2019). Acta Cryst. D75, 861–877.
Web of Science
CrossRef
IUCr Journals
Google Scholar
Luo, P., Xin, W., Guo, S., Li, X., Zhang, Q., Xu, Y., He, X., Wang, Y., Fan, W., Yuan, Q., Wu, K., Hu, W., Zhuang, Y., Xu, H. E. & Xie, X. (2025). Cell. Discov. 11, 7.
CrossRef
PubMed
Google Scholar
Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497.
CrossRef
CAS
PubMed
Web of Science
Google Scholar
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674.
Web of Science
CrossRef
CAS
IUCr Journals
Google Scholar
Mukherjee, S., Erramilli, S. K., Ammirati, M., Alvarez, F. J. D., Fennell, K. F., Purdy, M. D., Skrobek, B. M., Radziwon, K., Coukos, J., Kang, Y., Dutka, P., Gao, X., Qiu, X., Yeager, M., Xu, H. E., Han, S. & Kossiakoff, A. A. (2020). Nat. Commun. 11, 1598.
Google Scholar
Mukherjee, S., Ura, M., Hoey, R. J. & Kossiakoff, A. A. (2015). J. Mol. Biol. 427, 2707–2725.
Web of Science
CrossRef
PubMed
Google Scholar
Pan, Y., Ren, Z., Gao, S., Shen, J., Wang, L., Xu, Z., Yu, Y., Bachina, P., Zhang, H., Fan, X., Laganowsky, A., Yan, N. & Zhou, M. (2020). Nat. Commun. 11, 5686.
Web of Science
CrossRef
PubMed
Google Scholar
Shionoya, K., Park, J.-H., Ekimoto, T., Takeuchi, J. S., Mifune, J., Morita, T., Ishimoto, N., Umezawa, H., Yamamoto, K., Kobayashi, C., Kusunoki, A., Nomura, N., Iwata, S., Muramatsu, M., Tame, J. R. H., Ikeguchi, M., Park, S.-Y. & Watashi, K. (2024). Nat. Commun. 15, 9241.
CrossRef
PubMed
Google Scholar
Sverak, H. E., Yaeger, L. N., Worrall, L. J., Vacariu, C. M., Glenwright, A. J., Vuckovic, M., Al Azawi, Z.-D., Lamers, R. P., Marko, V. A., Skorupski, C., Soni, A. S., Tanner, M. E., Burrows, L. L. & Strynadka, N. C. J. (2024). Nat. Commun. 15, 9936.
CrossRef
PubMed
Google Scholar
Thomason, L. C., Costantino, N. & Court, D. L. (2007). Curr. Protoc. Mol. Biol. 79, 1.17.1–1.17.8.
CrossRef
Google Scholar
Trower, M. K. (1993). Biochim. Biophys. Acta, 1143, 109–111.
CrossRef
PubMed
Google Scholar
Tsutsumi, N., Mukherjee, S., Waghray, D., Janda, C. Y., Jude, K. M., Miao, Y., Burg, J. S., Aduri, N. G., Kossiakoff, A. A., Gati, C. & Garcia, K. C. (2020). eLife. 9, e58464.
CrossRef
PubMed
Google Scholar
Walsh, R. M., Roh, S.-H., Gharpure, A., Morales-Perez, C. L., Teng, J. & Hibbs, R. E. (2018). Nature, 557, 261–265.
Web of Science
CrossRef
CAS
PubMed
Google Scholar
Winter, G. (2010). J. Appl. Cryst. 43, 186–190.
Web of Science
CrossRef
CAS
IUCr Journals
Google Scholar
Winter, G., Waterman, D. G., Parkhurst, J. M., Brewster, A. S., Gildea, R. J., Gerstel, M., Fuentes-Montero, L., Vollmar, M., Michels-Clark, T., Young, I. D., Sauter, N. K. & Evans, G. (2018). Acta Cryst. D74, 85–97.
Web of Science
CrossRef
IUCr Journals
Google Scholar
Wu, S., Avila-Sakar, A., Kim, J., Booth, D. S., Greenberg, C. H., Rossi, A., Liao, M., Li, X., Alian, A., Griner, S. L., Juge, N., Yu, Y., Mergel, C. M., Chaparro-Riggers, J., Strop, P., Tampé, R., Edwards, R. H., Stroud, R. M., Craik, C. S. & Cheng, Y. (2012). Structure, 20, 582–592.
Web of Science
CrossRef
CAS
PubMed
Google Scholar
Zhang, L., Mobbs, J. I., Bennetts, F. M., Venugopal, H., Nguyen, A. T. N., Christopoulos, A., van der Es, D., Heitman, L. H., May, L. T., Glukhova, A. & Thal, D. M. (2025). Nat. Commun. 16, 7674.
CrossRef
PubMed
Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.

journal menu
access



